Breaking News, Financial News

Financial Report: Biogen Idec 3Q

Growth in the quarter was driven primarily by Tysabri sales, up 21% to $207 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 3Q 3Q Revenues: $1.1 billion (+3%) 3Q Earnings:$279.6 million (+35%) YTD Revenues: $3.3 billion (+7%) YTD Earnings: $671.1 million (+15%) Comments: Growth in the quarter was driven primarily by Tysabri sales, up 21% to $207 million. Avonex sales were $580 million (+1%). Revenues for the quarter included $284 million from Biogen Idec’s co-promotion arrangement with Genentech for Rituxan. Revenues from other products in the quarter were $15 million, compared to $14 milli...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters